Why it matters
The pharmaceuticals context.
Post-pandemic supply-chain pressure and bipartisan concern about US reliance on overseas active-pharmaceutical-ingredient (API) production drove an unprecedented wave of domestic pharmaceutical capacity announcements beginning in 2023. Eli Lilly, Novo Nordisk, and Johnson & Johnson lead capacity commitments that exceed any peer's investment in the prior two decades, much of it tied to GLP-1, oncology, and biologics demand.
Project record
At a glance
- Company
- Amgen (Science Innovation Center)
- Industry
- Pharmaceuticals
- Location
- Thousand Oaks, California
- Investment
- $600.0M
- Expected jobs
- 300
- Status
- Under Construction
- Announced
- Sep 12, 2024
- Expected opening
- Dec 1, 2026
- Added to tracker
- Feb 18, 2026
Sources
Official references
- Primary source https://www.amgen.com/newsroom
Related
Other projects to know
In California
- Advanced ManufacturingAtomic MachinesSanta Clara, California$156.0M305 jobs
- PharmaceuticalsGilead SciencesFoster City, California$847.0M450 jobs
- SemiconductorsApplied Materials (EPIC Center)Sunnyvale, California$4.00B2,000 jobs
- AerospaceNorthrop Grumman (B-21 Production)Palmdale, California$1.50B2,000 jobs
Back to the tracker/projects/amgen-science-innovation-center-thousand-oaks